Israel Active

Israel’s BrainStorm has received FDA approval to use its Nurown stem cells in a Phase 2 trial for the treatment of Multiple Sclerosis (MS). MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide.  Nurown is already in a Phase 3 trial for ALS .

The Radiology department at Israel’s Hadassah Medical Center in Jerusalem has been conducting joint research with Philips Medical Systems. It has resulted in a laboratory to study dual energy CT techniques using an experimental IQon Spectral CT scanner that is the first of its kind in the world.

I reported previously on Israel’s Cardiacsense and its watch that watches over your heart. Its sensors monitor heart activity and blood pressure. For those at risk of stroke or cardiac arrest it can detect arrythmia, arterial fibrillation and alert doctors. Watch COO Liat Shemesh on ILTV.

Engineers, researchers and physicians at Israel’s Technion literally work “hand in glove”. They developed artificial skin so burns victims can feel again. A robotic system to perform brain and spine surgery. Ingestible chemotherapy nano-delivery tubes and more.

Thanks to a major donation, Israel’s Weizmann Institute is establishing the Dr. Barry Sherman Institute for Medicinal Chemistry. Scientists will research compounds that can become therapies for autoimmune diseases, cancer, neurodegenerative diseases, and infectious diseases.

FDA designation for solid tumor treatment. (TY ) I reported previously that the AGI-134 solid tumor treatment from Israel’s BiolineRX showed promise. The U.S. FDA has just granted Biological Product Designation for the novel immunotherapy compound. Early trials show complete regression of tumors.

Israel’s E-Motion Medical has just received the CE Mark (i.e. European approval) for its E-Motion System, providing stimulation therapy that restores the natural motor function of the digestive system for patients with acute gastrointestinal dysmotility (GID).

Haifa’s Rambam Medical Center has set up a new daily program to treat young people up to age 30 in Northern Israel with eating disorders. Each patient receives an intensive, personized plan plus access to doctors, nurses, psychiatrists, psychologists, dieticians and social workers.

Dr. Noam Kaplan of Israel’s Technion Institute is a member of an International team of scientists that has decoded the genome of the fatal parasite Trypanosoma brucei – the cause of human “sleeping sickness”. It should help in the development of techniques to block the fatal disease.

I wrote previously that Israeli startup DayTwo will provide members of health care provider Clalit with personalized nutrition plans based on DNA analysis of gut microbiome. DayTwo is now setting up a $5 million lab in Rehovot, working with the Weizmann Institute.